Results · Apr-Jun 2026
Nath Biogene India Q1 FY27 results
Sales grew 16% to ₹328 crore from ₹284 crore in Apr-Jun 2025.
Operating profit fell 8% to ₹35.2 crore, an operating margin of 10.7% (down 2.8 points from a year ago).
Net profit fell 13% to ₹32.3 crore from ₹37.3 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +537%, net profit turns positive.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 328.4 | 283.7 | +16% |
| Operating profit (EBITDA) | 35.2 | 38.3 | −8% |
| Operating margin | 10.7% | 13.5% | −2.8 pts |
| Net profit | 32.3 | 37.3 | −13% |
Consolidated figures. Margins & ratios change in percentage points (pts).
The last 6 quarters
From the company's results filed on BSE (Consolidated). Business numbers only. Education & analysis, not investment advice or a recommendation.